(2023)
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.
Blood Res.
58,
4
(2023)
The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma.
FRONTIERS IN ONCOLOGY.
13,
(2023)
Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation.
FRONTIERS IN ONCOLOGY.
13,
(2023)
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study.
BLOOD CANCER JOURNAL.
13,
1
(2023)
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
NEW ENGLAND JOURNAL OF MEDICINE.
389,
4
(2023)
Clinical relevance of deep learning models in predicting the onset timing of cancer pain exacerbation.
SCIENTIFIC REPORTS.
13,
1
(2023)
Direct comparison of diagnostic and clinical values between Tc-99 m DPD and Tc-99 m PYP scintigraphy in patients with cardiac amyloidosis.
BMC MEDICAL IMAGING.
23,
1
(2023)
Retrospective analysis of diagnosis and therapeutic strategies for patients with hepatosplenic T cell lymphoma.
ANNALS OF HEMATOLOGY.
102,
7
(2023)
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation.
BLOOD CANCER JOURNAL.
13,
1
(2023)
Metabolic bulk volume predicts survival in a homogeneous cohort of stage II/III diffuse large B-cell lymphoma patients undergoing R-CHOP treatment.
FRONTIERS IN ONCOLOGY.
13,
(2023)
Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma.
CANCER MANAGEMENT AND RESEARCH.
15,
(2023)
TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
CANCER.
129,
10
(2023)
The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma.
BLOOD.
141,
18
(2023)
Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections.
FRONTIERS IN IMMUNOLOGY.
14,
(2023)
Comparison of histological and molecular features of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma (Jan, 10.1007/s00428-023-03493-x, 2023).
VIRCHOWS ARCHIV.
482,
5
(2023)
Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).
CANCER RESEARCH AND TREATMENT.
55,
2
(2023)
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
CANCER RESEARCH AND TREATMENT.
55,
3
(2023)
In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas.
FRONTIERS IN ONCOLOGY.
13,
(2023)
Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA.
23,
2
(2023)
Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma.
FRONTIERS IN ONCOLOGY.
12,
Conference Paper
(2009)
Treatment Outcome of Steroid-Refractory Chronic Graft-Versus-Host Disease with Weekly Rituximab Followed by Maintenance Rituximab: a KSBMT Multicenter Phase II Study.
The 51st annual meeting American society of hematology.
UNITED STATES
(2009)
COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH INTESTINAL NON-HODGKIN LYMPHOMA: CHEMOTHERAPY VERSUS SURGERY FOLLOWED BY CHEMOTHERAPY.
2009 ISOQOL meeting.
UNITED STATES
(2009)
Revised international prognostic index in diffuse large B-cell lymphoma of small and large intestine.
The 71st Annual meeting of the Japanese Society of Hematology.
JAPAN
(2009)
Immunoglobulin D multiple myeloma: Clinical presentation, response to therapy and prognostic factors in 77 patients.
제50차 대한혈액학회 춘계학술대회.
KOREA, REPUBLIC OF
(2009)
Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma.
제50차 대한혈액학회 춘계학술대회.
KOREA, REPUBLIC OF
(2009)
Primary mediastinal large B-cell lymphoma: A single center experience.
제50차 대한혈액학회 춘계학술대회.
KOREA, REPUBLIC OF
(2009)
Prognosis and qulaity of life in non-Hodgkin lymphoma of intestine: Multicenter analysis.
제50차 대한혈액학회 춘계학술대회.
KOREA, REPUBLIC OF
(2009)
The effect of bortezomib on bone metabolism of patients with multiple myeloma: a multicenter prospective study.
제50차 대한혈액학회 춘계학술대회.
KOREA, REPUBLIC OF
(2009)
Non-Hodgkin lymphoma of rare extranodal sites: Are they different from commonly involved sites?.
제50차 대한혈액학회 춘계학술대회.
KOREA, REPUBLIC OF
(2009)
Pulmonary marginal zone B-cell lymphoma of MALT type: Clinical manifestation and treatment outcomes.
제50차 대한혈액학회 춘계학술대회.
KOREA, REPUBLIC OF
(2009)
Multicenter phase II study of rituximab in patients with steroid-refractory chronic graft-versus-host disease: Results of interim analysis.
제13차 대한조혈모세포이식학회 동계학술대회.
KOREA, REPUBLIC OF